Atossa Genetics Target Price

Key Indicators . Target Price . Stocks . USA . 
Stock . Atossa Genetics
ATOS Stock  USD 5.60  -0.07  -1.23%   
How Atossa Genetics' Target Price is calculated and the current reading are covered. The current value corresponds to the latest disclosed financial data.
=

23.0

The Target Price value for Atossa Genetics reflects the latest reported data. The dataset is based on disclosed financial information.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Profitability
Analysis
Details
Earnings
Projections
Details

Target Price Peer Comparison

Analyzing Atossa Genetics relative to its peers on Target Price provides a clear view of competitive standing. Consistent deviation in Atossa Genetics' Target Price relative to peers may signal mispricing or competitive advantages. The range of Target Price values across Atossa Genetics peers indicates how much variation exists within the sector. This peer comparison supports a data-driven approach to evaluating Atossa Genetics investment merit.
Atossa Genetics is currently under evaluation in target price relative to competitors.

Important Fundamentals

Return On Equity TTM-0.63
Return On Asset TTM-0.37
Current Valuation9.26 M
Shares Outstanding8.61 M
Shares Owned By Insiders0.82 %
Shares Owned By Institutions22.08 %
Number Of Shares Shorted351.93 K
Price To Earnings TTM-0.62 X
Price To Book TTM1.28 X
Price To Sales TTM1,872 X
EBITDA TTM-37.12 M
Net Income TTM-34.77 M
Cash And Equivalents TTM125.54 M
Cash Per Share TTM0.99 X
Total Debt TTM8.26 M
Current Ratio TTM35.19 X
Book Value Per Share TTM4.57 X
Cash Flow From Operations TTM-29.76 M
Short Ratio TTM5.12 X
Earnings Per Share-4.37 X
Target Price23.0
Number Of Employees16
Trailing Beta1.25
Market Capitalization TTM48.22 M
Total Asset TTM47.61 M
Retained Earnings TTM-246.56 M
Working Capital TTM37.36 M
Current Asset TTM4.29 M
Current Liabilities TTM2.5 M
Net Asset47.61 M

Financial Metrics, Fundamentals & Methodology

Reviewing Atossa Genetics means checking how consistently revenue is converted into earnings and cash flow. Earnings persistence matters because stable results usually support more defensible valuation assumptions. Latest reported fundamentals for Atossa Genetics include EPS loss of 4.37, current ratio of 35.19 as of the latest reporting period.

Atossa Genetics analytics rely on periodic company reporting and market reference feeds, with quality checks and normalization applied. Analyst inputs may be included when coverage is available. Income statement, balance sheet, and cash-flow values follow GAAP or IFRS conventions as reported.

Editorial review and methodology oversight provided by: Michael Smolkin, Member of Macroaxis Board of Directors


 
Tools
Analysis
Directory
Company
2026 Macroaxis LLC Made with in San Francisco
Privacy Terms Widgets Feedback
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and conditions page.